A Study of Deucravacitinib to Treat LPP and FFA

Inclusion Criteria: * Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator. Subjects must give written, signed, and dated informed consent before any study related activity is performed. When appropriate, a legal representative will sign the informed consent according to local laws and regulation. * Subjects must have biopsy proven LPP/FFA and active disease. Exclusion Criteria: * On excluded therapies, not on a stable dose of a therapy, or incompletely washed out for a therapy. * Known hypersensitivity or other adverse reaction to Deucravacitinib (BMS-986165). * Variants of LPP/FFA deemed by the investigators to be inappropriate for Deucravacitinib (BMS-986165). * Pregnant or nursing (lactating) women (pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test). * Women of childbearing potential \[Post-menopausal or not of child-bearing potential is defined by 1 year of natural (spontaneous) amenorrhea or surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks ago. Oophorectomy alone must be confirmed by follow up hormone level assessment to be considered not of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception which includes: Total a…